The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease (RMD) patients, based on the efforts of the North American Task force.
Read Article
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read Article
The NEJM has reported the results of a study showing that avacopan, a C5a receptor inhibitor, is as effective as steroids at treating patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).
Read Article
Four major medical societies issued a joint statement of principles on safe use of hydroxychloroquine from the perspective of ocular toxicity.
Read Article
The 2021 Rheumatology Winter Clinical Symposium (RWCS) launched yesterday as a hybrid meeting. Led by exceptional teachers and researchers in rheumatology, this live and streaming conference had many highlights and takeaway messages. As always, this conference lends itself to data for the practi
Read Article
Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).
Read Article
The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.
Read Article
Dr. Jack Cush reviews nearly a dozen news and journal reports from the past 2 weeks on RheumNow.com, including the ACR's new COVID-19 vaccine guidance for patients with rheumatic disease.
Read Article
The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab (SEC) significantly improved axial signs and symptoms in psoriatic arthritis (PsA) patients with axial manifestations with inadequate NSAID response.
Read Article
The NEJM has published the results of the ACCT-2 Study, a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.
Read Article
As another year at RWCS in Maui wrapped up, I’m so thankful I had the opportunity to participate remotely. Thank you to Drs. Kavanaugh and Martin for providing a needed reprieve from the day to day grind in order learn from some of the best! Here are my day 4 #RWCS2021 pearls.
Read Article
A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs).
Read Article
Botson et al has reported that the combination of methotrexate (MTX) and IV pegloticase is safe and effective in patients with uncontrolled gout.
Read Article
As I attend RWCS virtually, I am always amazed by the amount of thought that goes into preparing great talks geared toward busy clinicians. Today, I am highlighting a few more pearls that you may find interesting as well.
Read Article
The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.
Read Article
Knee osteoarthritis (OA) patients using nonsteroidal anti-inflammatory drugs (NSAIDs) showed greater loss of medial minimum joint space width than did others taking other drugs, registry data indicated.
Read Article
Today I’ve included some research and clinical pearls as well as fodder for your post COVID-19 dinner party or trivia night! Enjoy!
Psoriatic Arthritis: 2020 Year in Review: with Drs. Alexis Ogdie, Artie Kavanaugh, and Eric Ruderman
Read Article
Katz, Arant and Loeser have published a comprehensive open-read overview of osteoarthritis (OA) of the hip and knee in JAMA; underscoring the impact, advances, disappointments and guidelines put forth.
Read Article
Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.
Read Article
Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in rheumatoid arthritis (RA) patients managed with a treat‐to‐ta
Read Article
